• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Rapid drop in serum testosterone after bilateral subcapsular orchiectomy.

作者信息

Arcadi J A

机构信息

Department of Surgery, Presbyterian Hospital, Whittier, California.

出版信息

J Surg Oncol. 1992 Jan;49(1):35-8. doi: 10.1002/jso.2930490109.

DOI:10.1002/jso.2930490109
PMID:1548879
Abstract

Bilateral subcapsular orchiectomy was performed in six patients with metastatic prostatic carcinoma. In these patients the serum levels of testosterone were determined serially up to twenty-four hours. Castrate levels of testosterone were achieved in about two and one-half hours. This is the first published report of such a rapid decrease in serum testosterone. Castrate levels of serum testosterone using the luteinizing hormone releasing hormone (LH-RH) agonists are achieved in fourteen to twenty-one days. The relative cost of orchiectomy and LH-RH agonists, for thirty-six months, was $2,042.00 and $12,780.00, respectively. LH-RH agonists may be effective for only a year. Urologists are urged to continue using bilateral subcapsular orchiectomy and not use LH-RH agonists in the management of metastatic prostatic carcinoma.

摘要

相似文献

1
Rapid drop in serum testosterone after bilateral subcapsular orchiectomy.
J Surg Oncol. 1992 Jan;49(1):35-8. doi: 10.1002/jso.2930490109.
2
Accuracy of serum luteinizing hormone and serum testosterone measurements to assess the efficacy of medical castration in prostate cancer patients.血清黄体生成素和血清睾酮测量评估前列腺癌患者医学去势疗效的准确性。
J Biomed Sci. 2017 Oct 22;24(1):81. doi: 10.1186/s12929-017-0386-0.
3
Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithm.促黄体生成素释放激素激动剂治疗期间未能达到睾酮去势水平:监测血清睾酮的必要性及治疗决策算法
J Urol. 2000 Sep;164(3 Pt 1):726-9. doi: 10.1097/00005392-200009010-00025.
4
Phase II trial with D-Trp-6-LH-RH in prostatic carcinoma: comparison with other hormonal agents.
Prostate. 1986;9(4):327-42. doi: 10.1002/pros.2990090404.
5
Epididymal sparing bilateral simple orchiectomy with epididymoplasty: preservation of esthetics and body image.保留附睾的双侧单纯睾丸切除术联合附睾成形术:保留美观和身体形象。
J Urol. 2005 Sep;174(3):893-7. doi: 10.1097/01.ju.0000172567.09442.b0.
6
Luteinizing Hormone-Releasing Hormone Agonists are Superior to Subcapsular Orchiectomy in Lowering Testosterone Levels of Men with Prostate Cancer: Results from a Randomized Clinical Trial.促黄体生成素释放激素激动剂在降低前列腺癌男性睾酮水平方面优于包膜下睾丸切除术:一项随机临床试验的结果
J Urol. 2017 Jun;197(6):1441-1447. doi: 10.1016/j.juro.2016.12.003. Epub 2016 Dec 9.
7
LHRH agonists in prostate cancer: frequency of treatment, serum testosterone measurement and castrate level: consensus opinion from a roundtable discussion.前列腺癌中的促黄体生成素释放激素激动剂:治疗频率、血清睾酮测量及去势水平:圆桌讨论的共识意见
Curr Med Res Opin. 2007 May;23(5):1077-80. doi: 10.1185/030079907x187973.
8
Serum luteinizing hormone (LH) biological activity in castrated patients with cancer of the prostate receiving a pure antiandrogen and in estrogen-pretreated patients treated with an LH-releasing hormone agonist and antiandrogen.接受纯抗雄激素治疗的前列腺癌去势患者以及接受促黄体生成素释放激素激动剂和抗雄激素治疗的雌激素预处理患者的血清促黄体生成素(LH)生物活性。
J Clin Endocrinol Metab. 1986 Aug;63(2):297-302. doi: 10.1210/jcem-63-2-297.
9
The time for serum testosterone to reach castrate level after bilateral orchiectomy or oral estrogen in the management of metastatic prostatic cancer.双侧睾丸切除术或口服雌激素治疗转移性前列腺癌后血清睾酮达到去势水平的时间。
Urology. 1994 Jun;43(6):834-7. doi: 10.1016/0090-4295(94)90145-7.
10
Prospective determination of the hormonal response after cessation of luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer.前列腺癌患者黄体生成素释放激素激动剂治疗停止后激素反应的前瞻性测定。
Urology. 1999 May;53(5):898-902; discussion 902-3. doi: 10.1016/s0090-4295(99)00061-8.

引用本文的文献

1
Surgical androgen deprivation therapy in advanced prostate cancer in patients of African descent: comparison of biochemical efficacy of bilateral total and subcapsular orchidectomy.在非洲裔患者的晚期前列腺癌中进行手术去势雄激素治疗:双侧全切除术和被膜下切除术的生化疗效比较。
Afr Health Sci. 2023 Mar;23(1):483-491. doi: 10.4314/ahs.v23i1.50.
2
The Finding of New In Vivo Metabolite Triptorelin (5-10) in Human Urine Using Liquid Chromatography Coupled with Ion Trap/Time-of-Flight Mass Spectrometry with Dimethyl Sulfoxide Additives in the Mobile Phase.采用在流动相中添加二甲基亚砜的液相色谱-离子阱/飞行时间质谱联用技术,在人尿液中发现新的体内代谢产物曲普瑞林(5-10)。
Molecules. 2023 Jun 6;28(12):4572. doi: 10.3390/molecules28124572.
3
Cosmetic Appeal, HRQoL, and Effectiveness of Simple and Pseudotesticular Techniques of Orchidectomy in Prostate Cancer.
前列腺癌中单纯性与假睾丸切除术的外观吸引力、健康相关生活质量及有效性
Prostate Cancer. 2021 Nov 26;2021:9968570. doi: 10.1155/2021/9968570. eCollection 2021.